When was HYCOR BioMedical founded?

HYCOR BioMedical was founded in 1981 and raised its 1st funding round 36 years after it was founded.

Where is HYCOR BioMedical located?

HYCOR BioMedical is headquartered in Garden Grove, United States.

How many employees does HYCOR BioMedical have?

As of Jun 30, 2026, the latest employee count at HYCOR BioMedical is 101.

Is HYCOR BioMedical a funded company?

HYCOR BioMedical is a funded company, having raised a total of $99.6M across 5 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Aug 01, 2017.

When was the latest funding round of HYCOR BioMedical?

HYCOR BioMedical's latest funding was a $***** Series D round on Dec 29, 2020, with participation from 0 investor.

Where does HYCOR BioMedical rank among its competitors?

HYCOR BioMedical ranks 6th amongst 90 active competitors, of which 16 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of HYCOR BioMedical?

HYCOR BioMedical's top competitors include Exagen, Daye and Proxim Diagnostics. Among them, Daye secured the most recent funding round in November, 2025.

HYCOR BioMedical - 2026 Company Profile, Funding & Competitors

Company Details

Hycor Biomedical develops IVD Instruments and associated reagents for autoimmune diseases and allergies. The company has two flagship products the HYTEC 288 Plus for allergy and autoimmune antibody testing, and the HYCOR Ultra-Sensitive System for ELISA.

Website: www.hycorbiomedical.com/
Social
Email ID: *****@hycorbiomedical.com, *****@hycorbiomedical.com
Phone Number: +1 **********

Key Metrics

Founded Year

1981

Location

Garden Grove, United States

Stage

Series D

Total Funding

$99.6M in 5 rounds

Latest Funding Round

Series D, Dec 29, 2020, $*****

Investors

GPB Capital & 1 more

Ranked

6^th among 90 active competitors

Employee Count

101 as on Jun 30, 2026

Similar Companies

Exagen & 71 more

View HYCOR BioMedical's full profile

HYCOR BioMedical has raised a total funding of $99.6M over 5 rounds. Its first funding round was on Aug 01, 2017. HYCOR BioMedical has 2 institutional investors.

Here is the list of recent funding rounds of HYCOR BioMedical:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 29, 2020	9760923	Series D	2954289	6388542	1233090	3665199
Sep 01, 2020	5555133	Series C	2228908	6937704	2652915	7144282
Jan 15, 2020	3539121	Series C	3364868	6054412	9391119	6059362

Access funding benchmarks and valuations. Sign up today!

View details of HYCOR BioMedical's funding rounds and investors

HYCOR BioMedical's employee count trend

HYCOR BioMedical has 101 employees as of Jun 26. Here is HYCOR BioMedical's employee count trend over the years:

Employee count trend for HYCOR BioMedical

Uncover HYCOR BioMedical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HYCOR BioMedical include Exagen, Daye and Proxim Diagnostics. Here is the list of Top 10 competitors of HYCOR BioMedical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Exagen 2002, Vista (United States), Public	Developer of diagnosis, prognosis and monitoring solutions for autoimmune connective diseases	$110M	HIG BioHealth Partners, Tullis Health Investors ... & 10 others	65/100
2nd	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Khosla Ventures, Salica Investments & 24 others	60/100
3rd	Proxim Diagnostics 2010, Sunnyvale (United States), Series B	Developer of a handheld immunodiagnostic device for cardiac vascular diseases	$22.9M	BioMerieux, UCLA Ventures & 1 others	58/100
4th	Oncimmune 2006, Cambridge (United States), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	IPF Partners, Balderton Capital & 9 others	58/100
5th	SmartHealth 1979, Irvine (United States), Series B	Developer precision diagnostics for vascular, metabolic, and oncological diseases	$17.3M	-	49/100
6th	HYCOR BioMedical 1981, Garden Grove (United States), Series D	Developer of diagnostic instruments and reagents for autoimmune diseases and allergies	$99.6M	GPB Capital & 1 others	49/100
7th	Virax Biolabs 2013, London (United Kingdom), Public	Developer and distributor of diagnostic test kits	-	-	43/100
8th	Kypha 2009, Dublin (Ireland), Series A	in-vitro diagnostic biomarker tests for inflammation and autoimmune disease	$16.8M	Billiken Angels Network, BioGenerator & 7 others	43/100
9th	Beikang Medical 2010, Suzhou (China), Public	Developer of NGS-based diagnostic solutions for neonatal	$36.5M	Broad Vision Funds, Yixiang Capital & 3 others	43/100
10th	Cell IDx 2012, San Diego (United States), Acquired	Advancing cancer diagnostics and improving lives through innovative solutions	$1.34M	-	41/100